TRACRIUM (atracurium besylate) by Pfizer is clinical pharmacology atracurium besylate is a nondepolarizing skeletal muscle relaxant. First approved in 1983.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
TRACRIUM (atracurium besylate) is a nondepolarizing skeletal muscle relaxant administered intravenously during anesthesia to facilitate intubation and surgical paralysis. It works by competitively antagonizing acetylcholine at the motor end-plate, with a duration of approximately one-third to one-half that of longer-acting agents like pancuronium. The drug is metabolized via organ-independent Hofmann elimination and ester hydrolysis, making it suitable for patients with hepatic or renal impairment.
As a legacy anesthetic agent nearing loss of exclusivity with moderate competitive pressure (30), the brand team is likely focused on defending market share rather than expansion; smaller, specialized commercial infrastructure remains.
CLINICAL PHARMACOLOGY Atracurium besylate is a nondepolarizing skeletal muscle relaxant. Nondepolarizing agents antagonize the neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the motor end-plate. This antagonism is inhibited, and neuromuscular…
Worked on TRACRIUM at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on TRACRIUM offers stability in a mature, established product with predictable market dynamics, but limited career growth potential or innovation exposure. Roles are operationally focused on defending market position against generics and established competitors rather than launching new indications or expanding clinical use.